Vial
- Company typePrivate
- Founded2020
- HeadquartersSan Francisco, United States
- Headcount101–250
- GTM typeB2B
- OfferingServices
Vial firmographics
Firmographics- Name
- Vial
- Legal name
- Vial Health Technology, Inc.
- Website
- https://vial.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Vial industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE), Cell-Based & Potency Assays (Bioassays) (HLAGADAH)
Keywords
Where Vial is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Vial business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Licensing Deals: Vial licenses its wholly owned assets in Oncology, Ophthalmology, Immunology & Inflammation, Cardiometabolic, and Rare Diseases to pharmaceutical partners. These are primarily antibody (mAb, TCE, bsAb) and RNA treatments (siRNA, ASO). Revenue is generated through upfront payments, milestone payments, and royalties from licensing agreements.
- Clinical Development Services: Vial leverages its vertically integrated Phase I clinic in Australia and proprietary clinical trial platform to conduct clinical trials, which may generate revenue through partnerships with biotech sponsors.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Vial product offering
Product offeringCore offering
Vial is a clinical-stage biotechnology company that designs and develops first and best-in-class biologics and RNA therapeutics focused on Immunology & Inflammation, including a half-life-extended IL-13 x TSLP bispecific antibody for asthma and an INHBE siRNA therapy for obesity. The company combines AI-enabled target discovery, iterative molecule design, and high-throughput experimental validation with a vertically integrated Phase I clinical trial operation in Australia, and commercializes its pipeline assets through licensing and partnership deals with pharmaceutical sponsors.
Product overview
Vial is a clinical-stage biotechnology company advancing first and best-in-class biologics and RNA therapeutics in Immunology & Inflammation. The company's portfolio includes two core pipeline programs: IL-13 x TSLP (a half-life-extended bispecific antibody in Phase 1 for asthma and atopic dermatitis) and INHBE siRNA (a liver-targeted obesity therapy in Phase 1). Vial's technology platform enables automated clinical trials with vertical integration including a proprietary Phase I clinic in Australia, computational therapeutic design, and high-throughput experimental validation capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- IL-13 x TSLP (VIAL-IL13xTSLP) A half-life-extended bispecific antibody targeting IL-13 and TSLP for the treatment of mild-to-moderate asthma, atopic dermatitis, and chronic sinusitis. Engineered for quarterly-to-biannual dosing with picomolar binding affinities for both targets, offered to pharmaceutical partners for licensing.
- INHBE (VIAL-INHBE) siRNA A liver-targeted siRNA therapy designed to block Activin E signaling and increase lipolysis for fat-selective weight loss while preserving muscle mass. Evaluated for obesity and cardiometabolic diseases, with potential use alone or in combination with GLP-1 therapies, offered to pharmaceutical partners for licensing.
- Clinical Trial Platform Vial's proprietary technology platform that powers automated clinical trials with vertical integration, scale, and technology, leveraging a Phase I clinic in Australia to deliver Phase I clinical trials at 80%+ lower cost than typical operations and automated trial processes with 90%+ cost savings.
Quantifiable outcome
- Phase I clinic costs 80%+ cheaper than typical clinical trial operations
- +6 more outcomes
Companies that use Vial
Customer profileSegments2 records
Ideal customer profiles1 record
Vial technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature8 records
Vial partnerships and signals
Strategic signalScale indicators5 records
Recent moves6 records
Expansion highlights5 records
Vial competitors and assessment
Company assessmentEmerging players
- Adagene: Clinical-stage antibody engineering biotech with platform-based discovery capabilities. Comparable antibody engineering focus and similar clinical-stage size profile to Vial.
- Upstream Bio: Clinical-stage biotech developing TSLP-targeting antibodies for inflammatory diseases. Directly comparable therapeutic target overlap with Vial's IL-13 x TSLP program and similar immunology-and-inflammation focus.
- BioAge Labs: Clinical-stage biotech developing therapeutics for metabolic diseases including obesity, leveraging platform discovery. Directly comparable to VIAL-INHBE in obesity mechanism and cardiometabolic focus.
- Erasca: Clinical-stage oncology biotech with multiple pipeline programs and similar employee scale (~50–100) and venture-backed profile. Comparable size and clinical-stage structure, though focused on oncology rather than immunology.
- Centessa Pharmaceuticals: Clinical-stage biotech operating a portfolio of asset-centric programs across multiple therapeutic areas. Comparable portfolio model and licensing approach to Vial, with similar stage and capital profile.
Direct peers
- Recursion Pharmaceuticals: Clinical-stage biotech combining AI-driven target discovery with high-throughput experimental validation, very similar in approach to Vial. Both are platform-driven biotechs leveraging computation to compress drug development timelines.
- Generate Biomedicines: AI-first biologics company using generative models to design novel antibody and protein therapeutics. Directly comparable to Vial's AI-designed biologics approach, including bispecific antibody design.
- AbCellera Biologics: Antibody discovery and engineering platform with AI-augmented screening capabilities. Comparable to Vial's bispecific antibody engineering work, though AbCellera is a more mature platform business.
- Insitro: Machine learning-driven drug discovery company developing therapeutics for metabolic and neurological diseases. Comparable AI-driven discovery and validation methodology to Vial, with similar clinical-stage profile.
- Schrödinger: Computational drug design platform combining physics-based simulation with AI/ML for molecule design. Comparable technology stack to Vial's AI-driven molecule design, and serves a similar biotech customer base.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Vial social profiles
Digital presenceVial financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vial leadership team
Management profileNumber of profiles
Profiles13 records
Vial funding detail
Funding detailFunding overview
Funding rounds4 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vial M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vial
What does Vial do?
Vial is a clinical-stage biotechnology company that designs and develops first and best-in-class biologics and RNA therapeutics focused on Immunology & Inflammation, including a half-life-extended IL-13 x TSLP bispecific antibody for asthma and an INHBE siRNA therapy for obesity. The company combines AI-enabled target discovery, iterative molecule design, and high-throughput experimental validation with a vertically integrated Phase I clinical trial operation in Australia, and commercializes its pipeline assets through licensing and partnership deals with pharmaceutical sponsors.
Is Vial a public or private company?
Vial is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vial founded?
Vial was founded in 2020. It employs 101 to 250 people.
Where is Vial based?
Vial is headquartered in San Francisco, United States, in the North America region.
How does Vial make money?
Two revenue lines are on record. Licensing Deals are the primary driver. The others are clinical Development Services.
Who are Vial's main competitors?
Emerging players on record are Adagene, Upstream Bio, BioAge Labs, Erasca and Centessa Pharmaceuticals. Direct peers are Recursion Pharmaceuticals, Generate Biomedicines, AbCellera Biologics, Insitro and Schrödinger.
Does Vial have an API?
No public API is recorded for Vial.
What industry is Vial in?
Vial's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 541714 and its SIC code is 2836.